Blue skies for Cerulean? Cancer nanobiotech files for $75M IPO
Despite a phase IIb miss this time last year for lead compound CRLX101 in advanced non-small-cell lung cancer (NSCLC), Cerulean Pharma Inc. vowed to plow forward with its nanopharmaceutical platform. After dosing the first patient last month in a phase II trial of CRLX101, the company is moving ahead in a big way, filing Monday with the SEC to raise up to $75 million in an initial public offering.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST